Data on Gilead's remdesivir show no benefit for coronavirus patients

Data on Gilead's remdesivir show no benefit for coronavirus patients

New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope

By ED SILVERMAN AND ADAM FEUERSTEIN AND MATTHEW HERPER

FEATURECHINA VIA AP

The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients in China with Covid-19 or prevent them from dying.

READ MORE